

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4445626

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JANSSEN-CILAG, S.A.	12/03/2014
RECEIVING PARTY DATA		
Name:	JANSSEN PHARMACEUTICA NV	
Street Address:	TURNHOUTSEWEG 30	
City:	BEERSE	
State/Country:	BELGIUM	
Postal Code:	B2340	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	15533308	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	jnjuspatent@corus.jnj.com	
Correspondent Name:	JOSEPH SHIRTZ	
Address Line 1:	ONE JOHNSON AND JOHNSON PLAZA	
Address Line 4:	NEW BRUNSWICK, NEW JERSEY 08933	
ATTORNEY DOCKET NUMBER:	JAB6045USPCT	
NAME OF SUBMITTER:	SONNY NKANSA	
SIGNATURE:	/Sonny Nkansa/	
DATE SIGNED:	06/06/2017	
Total Attachments: 1		
source=JAB6045_GENERAL_ASSIGNMENTS_CILAG_TO_JNV#page1.tif		

General Assignment

WHEREAS, Janssen-Cilag, S.A., having its place of business at Edificio Johnson & Johnson, Paseo de las Doce Estrellas, 5-7, 5^a planta, Campo de las Naciones, 28042 Madrid, Spain (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS"

for which on the 3rd day of December 2014, European Patent Application no. EP 14196082.3 was filed at the European Patent Office;

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignor's entire right, title and interest therein, including the right to claim priority thereof,


NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 3rd day of December 2014.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen-Cilag, S.A.



Frank Daelemans
Authorized Signatory
Janssen-Cilag, S.A.

For Janssen Pharmaceutica NV



Luc Quaghebeur
Authorized Signatory
Janssen Pharmaceutica NV